With 0.73 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.21 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.94 whereas the lowest price it dropped to was $1.78. The 52-week range on BIVI shows that it touched its highest point at $75.00 and its lowest point at $1.42 during that stretch. It currently has a 1-year price target of $12.00. Beta for the stock currently stands at 0.66.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BIVI was up-trending over the past week, with a rise of 14.37%, but this was up by 6.70% over a month. Three-month performance dropped to -82.64% while six-month performance fell -81.72%. The stock lost -90.45% in the past year, while it has lost -92.33% so far this year.
Float and Shares Shorts:
At present, 7.53 million BIVI shares are outstanding with a float of 7.29 million shares on hand for trading. On 2025-08-15, short shares totaled 0.16 million, which was 213.99999999999997 higher than short shares on 1752537600. In addition to Mr. Cuong Viet Do M.B.A. as the firm’s President, CEO & Director, Ms. Joanne Wendy Kim CPA serves as its CFO, Treasurer & Corporate Secretary.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, BIVI reported revenue of $0.0 and operating income of -$3663085.0. The EBITDA in the recently reported quarter was -$3426799.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BIVI since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BIVI analysts setting a high price target of 12.0 and a low target of 12.0, the average target price over the next 12 months is 12.0. Based on these targets, BIVI could surge 528.27% to reach the target high and rise by 528.27% to reach the target low. Reaching the average price target will result in a growth of 528.27% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$101 being high and -$101 being low. For BIVI, this leads to a yearly average estimate of -$101. Based on analyst estimates, the high estimate for the next quarter is -$0.92 and the low estimate is -$0.92. The average estimate for the next quarter is thus -$0.92.
